Boom expected in global COVID-19 drug associated APIs market
Market set to grow as companies face fewer operational restrictions and COVID-19 drug development continues at pace
The global market for active pharmaceutical ingredients (APIs) used in the manufacturing of COVID-19 drugs is expected to boom this year, according to a new report on ResearchAndMarkets.
The market is forecast to grow from $5.55 billion in 2021 to $5.99 billion in 2022 at a compound annual growth rate of 7.9%. It is expected to reach $7.55 billion in 2026.
The report’s authors say this growth is largely due to a global relaxation of COVID-19 restrictions, allowing companies to resume operations without the challenges posed by social distancing and remote working requirements. The market was also stunted by disruptions to medical product supply chains during the pandemic, exacerbated by export restrictions implemented in some countries. Now that companies are recovering, the market is expected to surge.
The main classes of drugs in COVID-19 drug-associated APIs are antimalarials, bronchodilators, antibiotics, antivirals and others. The different types of drugs include generic and branded and involve various business modes such as captive API (produced internally by pharma companies) and merchant API (produced by third-party providers).
Currently North America is the largest region in the COVID-19 drug-associated APIs market, but the Middle East is earmarked to become the fastest growing region in the coming years.
Key players in the market include Dr. Reddy's Laboratories, Lianyungang Guike Pharmaceutical, Alembic Pharmaceutical, Wockhardt, Sandoz Srl, Lupin Limited, Aurobindo Pharma, Shanghai Shyndec Pharmaceutical (Haimen) and Yatai Pharma.
They are now faced with the challenge of ensuring adequate plant and production capacity to meet the increasing demand. Some have already expanded their operations, with Alembic Pharmaceuticals ramping up production of azithromycin in 2020 and FUJIFILM announcing the expansion of its manufacturing capacity and increase in the production of influenza antiviral Avigan.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance